Summary: Cullinan Therapeutics (CGEM) stock surged ~58% last week after positive data for CD19-targeting therapy similar to competitor Amgen's Blincyto, showing efficacy against autoimmune diseases like rheumatoid arthritis and systemic sclerosis.
Full article